Quick Take
Lantern Pharma (LTRN) has filed to raise $28.75 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is developing a pipeline of drug candidates for the treatment of prostate, lung and other cancers.
LTRN seeks to use its proprietary AI platform to better identify existing or past failed drug programs that may be repurposed or otherwise enhanced to achieve development success.
I’ll provide an opinion when we learn more IPO details from management.
Company & Technology
Dallas, Texas-based Lantern was founded to use